(Press-News.org) Barcelona, Spain: Patients with a form of advanced colorectal cancer that is driven by a mutated version of the BRAF gene have limited treatment options available. However, results from a multi-centre clinical trial suggest that the cancer may respond to a combination of three targeted drugs.
Professor Josep Tabernero, head of the medical oncology department at Vall d'Hebron University Hospital and director of the Vall d'Hebron Institute of Oncology, Barcelona, Spain, will tell the 26th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona today (Friday) that he and colleagues in a number of different countries [2] are investigating a BRAF inhibitor, encorafenib, combined with cetuximab, which inhibits the epidermal growth factor receptor (EGFR), with or without a third drug, alpelisib, which inhibits another cancer-causing pathway called PI3K, in a phase I clinical trial for patients with advanced BRAF-mutated colorectal cancer.
"Among the 54 patients enrolled in the dose-finding part of the trial, we found that tumours shrank in 23% of the patients receiving encorafenib and cetuximab, and in 32% of patients receiving a combination of all three drugs," he will say. "The median length of time that patients survived without their disease worsening ranged from 16 weeks for patients receiving the dual therapy to 19 weeks for those receiving all three drugs. While we were not comparing patients on these therapies with patients receiving the normal standard of care, these progression-free survival times are nearly double those for patients who have been treated in the past with standard of care therapies."
He will continue: "Patients with advanced colorectal cancer with tumours that bear BRAF mutations invariably fail to respond meaningfully to standard treatments and ultimately face a dismal prognosis. Further, recent efforts aimed at using a single agent to inhibit BRAF in colorectal tumours have largely disappointed in improving response to therapy in these patients. Spurred by promising preclinical results, and in order to avoid mechanisms of primary resistance to therapy, we have tested the safety and efficacy of a novel approach to treatment, combining a 'trio' of existing therapies in patients.
"While it is still early days and these are preliminary data, this combinatorial strategy is showing improved efficacy, extended progression free survival, with manageable side-effects in patients. This study, therefore, represents a significant step forward in providing metastatic colorectal cancer patients with fresh hope and a new therapeutic avenue."
Patients on the trial were treated with encorafenib, taken orally once a day, together with a standard intravenous dose of cetuximab (400 mg/m2 for the initial, loading dose, followed by 250 mg/m2 weekly). In addition, 28 of the patients also received an oral dose of alpelisib once a day.
The researchers found that the combination of drugs was generally well tolerated by the patients. Adverse side-effects for the dual therapy included fatigue, reactions to the infusion and low phosphate levels in the blood. The addition of alpelisib also caused nausea, diarrhoea, skin rashes, high blood sugar levels and increased levels of lipase (a protein released by the pancreas that helps the body to absorb fat).
The genetic make-up of the tumours was analysed to see how this compared with the responses to treatment seen in the patients. "This work has shown that BRAF-mutated colorectal cancer is a diverse disease and that a number of key, cancer-related pathways are involved, including the PI3K and WNT pathways," says Prof Tabernero. "This could explain why drugs that target different pathways are more effective when used together."
The trial is continuing to enrol patients - up to 50 for each arm of the trial - randomising them to either the dual or triple combination of drugs in order to see which is the most promising regimen.
Professor Jean-Charles Soria, chair of the scientific committee for the EORTC-NCI-AACR Symposium and Director of the Site de Recherche Intégrée sur le Cancer (SIRIC) Socrate project at Gustave Roussy Cancer Campus, France, commented: "BRAF mutants represent a genetically well-defined sub-group of colorectal cancers. In such patients monotherapy with BRAF inhibitors lacks activity in clear contrast with the indisputable activity observed in BRAF mutant melanoma or non-small cell lung cancer. Here a dual blockade of BRAF and EGFR, as well as a triple blockade of BRAF, EGFR and PI3K demonstrate clear anti-tumour activity in the vast majority of patients with tumour shrinkage in 25-30% and stable disease in 54-60%."
INFORMATION:
[1] EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association for Cancer Research].
[2] The phase I clinical trial is being run in Spain, France, The Netherlands, Germany, Japan, The USA and Canada.
(PHILADELPHIA) - Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disease that primarily kills motor neurons, leading to paralysis and death 2 to 5 years from diagnosis. Currently ALS has no cure. Despite promising early-stage research, the majority of drugs in development for ALS have failed. Now researchers have uncovered a possible explanation. In a study published November 20th in the Annals of Clinical and Translational Neurology, researchers show that the brain's machinery for pumping out toxins is ratcheted up in ALS ...
A lot of research has shown that poor regulation of the serotonin system, caused by certain genetic variations, can increase the risk of developing psychiatric illnesses such as autism, depression, or anxiety disorders. Furthermore, genetic variations in the components of the serotonin system can interact with stress experienced during the foetal stages and/or early childhood, which can also increase the risk of developing psychiatric problems later on.
In order to better understand serotonin's influence in the developing brain, Alexandre Dayer's team in the Psychiatry ...
Working at the edge of a coal mine in India, a team of Johns Hopkins researchers and colleagues have filled in a major gap in science's understanding of the evolution of a group of animals that includes horses and rhinos. That group likely originated on the subcontinent when it was still an island headed swiftly for collision with Asia, the researchers report Nov. 20 in the online journal Nature Communications.
Modern horses, rhinos and tapirs belong to a biological group, or order, called Perissodactyla. Also known as "odd-toed ungulates," animals in the order have, ...
Bremerhaven/Germany, 20 November 2014. Scientists from the Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research (AWI) have identified a possible source of carbon dioxide (CO2) and other greenhouse gases that were abruptly released to the atmosphere in large quantities around 14,600 years ago. According to this new interpretation, the CO2 - released during the onset of the Bølling/Allerød warm period - presumably had their origin in thawing Arctic permafrost soil and amplified the initial warming through positive feedback. The study now appears ...
The residents of Longyearbyen, the largest town on the Norwegian arctic island archipelago of Svalbard, remember it as the week that the weather gods caused trouble.
Temperatures were ridiculously warm - and reached a maximum of nearly +8 degrees C in one location at a time when mean temperatures are normally -15 degrees C. It rained in record amounts.
Snow packs became so saturated that slushy snow avalanches from the mountains surrounding Longyearbyen covered roads and took out a major pedestrian bridge.
Snowy streets and the tundra were transformed into icy, ...
MEDFORD/SOMERVILLE, Mass-- Tufts University School of Engineering researchers and collaborators from Texas A&M University have published the first research to use computational modeling to predict and identify the metabolic products of gastrointestinal (GI) tract microorganisms. Understanding these metabolic products, or metabolites, could influence how clinicians diagnose and treat GI diseases, as well as many other metabolic and neurological diseases increasingly associated with compromised GI function. The research appears in the November 20 edition of Nature Communications ...
AMHERST, Mass. -- Predicting the beginning of influenza outbreaks is notoriously difficult, and can affect prevention and control efforts. Now, just in time for flu season, biostatistician Nicholas Reich of the University of Massachusetts Amherst and colleagues at Johns Hopkins have devised a simple yet accurate method for hospitals and public health departments to determine the onset of elevated influenza activity at the community level.
Hospital epidemiologists and others responsible for public health decisions do not declare the start of flu season lightly, Reich ...
A team of scientists hope to trace the origins of gamma-ray bursts with the aid of giant space 'microphones'.
Researchers at Cardiff University are trying to work out the possible sounds scientists might expect to hear when the ultra-sensitive LIGO and Virgo detectors are switched on in 2015.
It's hoped the kilometre-scale microphones will detect gravitational waves created by black holes, and shed light on the origins of the Universe.
Researchers Dr Francesco Pannarale and Dr Frank Ohme, in Cardiff University's School of Physics and Astronomy, are exploring the potential ...
(PHILADELPHIA) - Pulmonary fibrosis has no cure. It's caused by scarring that seems to feed on itself, with the tougher, less elastic tissue replacing the ever moving and stretching lung, making it increasingly difficult for patients to breathe. Researchers debate whether the lung tissue is directly damaged, or whether immune cells initiate the scarring process - an important distinction when trying to find new ways to battle the disease. Now research shows that both processes may be important, and suggest a new direction for developing novel therapies. The work will publish ...
WASHINGTON, DC, November 17, 2014 -- A new study finds that having job authority increases symptoms of depression among women, but decreases them among men.
"Women with job authority -- the ability to hire, fire, and influence pay -- have significantly more symptoms of depression than women without this power," said Tetyana Pudrovska, an assistant professor in the Department of Sociology at the University of Texas at Austin and the lead author of the study. "In contrast, men with job authority have fewer symptoms of depression than men without such power."
Titled, ...
